FPI-2265

Phase 2Small molecule

FFusion Pharmaceuticals Inc.

FPI-2265 is one of 91 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerRecruiting

Prostate CancerActive, not recruiting

Metastatic Castration-Resistant Prostate CancerActive, not recruiting

Metastatic Prostate CancerPreclinical

Recruiting

Prostate CancerPhase 2

Active, not recruiting

Metastatic Castration-Resistant Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

FPI-2265

FFusion Pharmaceuticals Inc.

Phase 2

2 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Prostate Cancer

NCT05219500

Q2 2027

Phase 2Active, not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06909825

Q3 2029

PreclinicalRecruiting

Metastatic Prostate Cancer

NCT07590934

Q1 2031

Phase 2Recruiting

Prostate Cancer

NCT06402331

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting·FFusion Pharmaceuticals Inc.·Phase 2·NCT06402331·100 enrolled

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Active, not recruiting·FFusion Pharmaceuticals Inc.·Phase 2·NCT05219500·115 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Active, not recruiting·FFusion Pharmaceuticals Inc.·Phase 2·NCT06909825·85 enrolled

Metastatic Prostate Cancer1 trial

A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07590934·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for FPI-2265. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FPI-2265 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FPI-2265. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fusion Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFusion Pharmaceuticals Inc.

FPI-2265

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q3 2029

Q1 2031

Trials by Indication[1]

Prostate Cancer2 trials

Metastatic Castration-Resistant Prostate Cancer1 trial

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News